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Primary hyperparathyroidism (PHPT) is one of the most
frequent endocrine disease in developed countries. It
mainly occurs as sporadic cases (about 90-95% of cas-
es), while only the remaining 5-10% is represented by fa-
milial inherited parathyroid disorders due to causative
mutations in specific target genes. Clinical variability
among the different familial parathyroid syndromes is
generally linked to the specific mutated gene and it can
predispose subjects to different manifestations of
parathyroid pathology, various degrees of PHPT severi-
ty, persistence and/or after-surgery recurrences. Genetic
tests is helpful in differential diagnosis favouring the
recognition of the specific familial PHPT syndrome and,
subsequently, in planning the most suitable surgical
procedures and/or pharmacological interventions. More-
over, genetic test is important to recognise mutation car-
riers, within PHPT familial forms, even before the ap-
pearance of biochemical and/or clinical symptoms.
This review resumes general concepts about genetic di-
agnosis of PHPT in familial hereditary syndromes,
specifically describing why, when, and which genetic
screenings should be performed in every specific PHPT-
associated parathyroid disease.
KEY WORDS: primary hyperparathyroidism; parathyroid adenoma; genetic test;
MEN; FHH; FIHP.
Introduction
Primary hyperparathyroidism (PHPT) is one of the most fre-
quent endocrine diseases in developed countries (1), char-
acterised by excessive hypersecretion of parathyroid hor-
mone (PTH) by parathyroid glands, resulting in a constant
high serum calcium level. PHPT is due to the presence of a
benign single parathyroid adenoma in 80% of the cases, to
multiple parathyroid adenoma and/or multiglandular hyper-
plasia in 15-20% of the cases or to parathyroid carcinoma in
only 1% of the cases (2). 
Sporadic PHPT cases represent about 90-95% of all PHPT,
mostly sustained by a single parathyroid adenoma. The re-
maining 5-10% of cases occurs within familial inherited
parathyroid disorders such as multiple endocrine neoplasia
type 1 (MEN1), multiple endocrine neoplasia type 2A
(MEN2A), multiple endocrine neoplasia type 4 (MEN4), fa-
milial hypocalciuric hypercalcemia syndrome (FHH), neona-
tal severe hyperparathyroidism (NSHPT), HPT-jaw tumour
(HPT-JT) and familial isolated PHPT (FIPH) (Table 1). They
are mainly sustained by multiglandular disease and often
characterized by an earlier age of onset with respect to spo-
radic PHPT.
PHPT is mostly asymptomatic. In the symptomatic forms it
can be associated with increased morbidity because of sec-
ondary osteoporosis, nephrolithiasis, kidney stones, neuro-
muscular effects and cognitive changes (3), due to the
chronic increased level of circulating PTH and calcium.
Since PHPT can present a longstanding asymptomatic
course, particularly in case of familial forms and hereditary
multiple cancer syndromes, the systematic assessment of
the genetic risk is very important to early recognise at risk in-
dividuals even before clinical symptoms. The diagnosis of
PHPT is biochemical. Indeed, biochemical analyses are able
to recognise signs of PHPT about 10 years earlier than in-
strumental evidence of gland involvement. Genetic testing
permits the identification of at risk individuals even before
any biological, biochemical and clinical manifestation, provid-
ing the opportunity for routine preventive screenings and
early treatments, particularly in preclinical, asymptomatic dis-
ease in relatives of index cases, allowing the recognition of
familial PHPT associated syndrome. Although a specific phe-
notype-to-genotype correlation does not exist, there is a cer-
tain degree of clinical variability due to the specific causative
genetic alteration that can predispose subjects to different
manifestations of parathyroid pathology, various degrees of
PHPT severity, persistence and/or after-surgery recurrences,
and, subsequently, the management of PHPT differs among
the different familial syndromes (Table 1). Therefore, it is
useful to identify the specific syndrome before planning sur-
gical procedures and/or any pharmacological intervention. 
This review resumes general concepts about genetic diagno-
sis of PHPT in familial hereditary syndromes and in sporadic
cases, specifically describing why, when, and which genetic
screenings should be performed in every specific PHPT-as-
sociated parathyroid disease and which are the benefits of
genetic test application in differential diagnosis and clinical
management of PHPT.
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Genetic testing in PHPT in multiple endocrine neoplasia
type 1 (MEN1) 
Multiple endocrine neoplasia type 1 (MEN1; OMIM pheno-
type #131100) is a rare endocrine disorder presenting with
varying combinations of PHPT, endocrine pancreatic tu-
mours, and pituitary adenomas, but it can include combina-
tions of more than 20 endocrine and non-endocrine tumours
such as carcinoids, lipomas, and skin tumours. PHPT, most-
ly caused by parathyroid multiple adenomas and/or multi -
glandular hyperplasia, represents the first clinical manifesta-
tion in about 90% of patients (4) with a typical onset between
20 and 25 years, three decades earlier than its sporadic
counterpart and is the most common clinical feature of this
syndrome, with a penetrance reaching the 100% after 50
years of age. 
This disease shows an autosomal dominant pattern of inheri-
tance. The responsible gene, the oncosuppressor gene
MEN1 (OMIM gene 613733), encoding menin (a nuclear pro-
tein involved in the negative regulation of cell cycle progres-
sion, in the control of DNA integrity, in the regulation of
apoptosis, etc.), has been identified in 1997 in the long arm
of chromosome 11 (locus 11q13). Since then a specific mu-
tational screening test is available for this syndrome. One in-
activating mutation of MEN1 gene can be inherited by one of
the parent (familial form) or developed de novo at embryo
level (sporadic form), giving subjects the predisposition to
develop the syndrome. The second wild type copy of the
gene is lost during lifetime at tissue somatic level, generating
specific endocrine and non-endocrine MEN1-associated tu-
mours, according to Knudson’s two hits hypothesis for tu-
mour suppressor genes. The exact molecular role of MEN1’s
protein, menin, in MEN1 tumorigenesis is not yet well under-
stood, but it is surely related to the important functions that
this protein has in regulation of cell cycle, DNA replication
and integrity maintenance, gene transcription, signal trans-
duction, etc. An extensive review in 2008 described over
1,300 different germinal (1,133) or somatic (203) mutations
and 24 benign polymorphisms that have been identified, by
mutation screening of the MEN1 gene, all along the entire
gene without any mutational hot spot (i.e. a DNA sequence
and/or region of high mutation susceptibility) (5). A 2016 up-
date reported 208 novel further germline MEN1 mutations,
identified in patients with MEN1 syndrome between 2007
and 2015 (6). Unfortunately, none of the described MEN1
mutations has been associated to a peculiar clinical pheno-
type, even within members of the same family, thus a geno-
type-to-phenotype correlation does not exist. Therefore, un-
related individuals with different mutations may present with
the same clinical phenotype, making impossible to foresee
the course of the disease by the result of genetic test and to
design a personal predictive and therapeutic plan. Despite
this limitation, the use of genetic test in MEN1 has been
shown to reduce the morbidity and mortality of the syn-
drome. Indeed, a positive test in asymptomatic subjects with-
in a family with a known mutation of the MEN1 gene, even if
it does not lead to immediate surgical and medical interven-
tions, is an indication for earlier and more frequent preven-
tive instrumental and biochemical screenings for MEN1-as-
sociated lesions (Table 2). Conversely, a negative test in in-
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Table 1 - Main clinical characteristics of familial hereditary forms of PHPT. 
 
Syndrome Mean age of 
onset 
Parathyroid pathology Clinical treatment 
MEN1 20-25 years Multiglandular hyperplasia 
and/or adenoma 
Subtotal parathyroidectomy of hyperplastic and/or adenomatous 
parathyroids; or total parathyroidectomy with healthy tissue reimplantation 
in the non-dominant forearm, in case of  pathological involvement of all 
four parathyroids 
MEN2A Over 30 years Single or multiglandular 
hyperplasia and/or 
adenoma 
Specific resection on only the hyperplastic and/or adenomatous 
parathyroids 
MEN4 Over 45 years Single or multiglandular 
hyperplasia and/or 
adenoma 
Specific resection on only the hyperplastic and/or adenomatous 
parathyroids 
FHH All ages Multiglandular mildly 
hyperplastic parathyroids 
Parathyroidectomy is not only unnecessary but also inappropriate, since it 
does not cure FHH-associated hypercalcemia 
NSHPT At birth or within 
the first six 




HPT-JT Over 30 years Single or multiglandular 
(usually two glands) cystic 
adenoma.  
Carcinomas in 10-15% of 
cases 
Subtotal parathyroidectomy of adenomatous and/or carcinomatous 
parathyroids, or total parathyroidectomy, with healthy tissue reimplantation 
in the non-dominant forearm, in case of adenoma involvement of all four 
parathyroids 
 
FIPH N.R. Single or multiglandular 
adenoma 
Subtotal parathyroidectomy of adenomatous parathyroids, or total 
parathyroidectomy, with healthy tissue reimplantation in the non-dominant 
forearm, in case of adenoma involvement of all four parathyroids 
Footnotes: N.R. = not reported 
 
N.R. = not reported.
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Gene mutation Recommended age of 
begin screenings 
Type of screenings Frequency 
MEN1 MEN1 Any inactivating 
MEN1 mutation 
Age of 5 Serum concentration of 
prolactin 
Yearly 
Age of 8 Fasting total serum calcium 
concentration (corrected 
for albumin) and/or ionized-
serum calcium 
concentration. Fasting 
serum concentration of full-
length PTH 
Yearly 
Age of 20  Fasting serum gastrin 
concentration 
Yearly 










MEN2A RET C634R/G/F/S/W/Y Age of 8 Fasting total serum calcium 
concentration (corrected 
for albumin) and/or ionized-
serum calcium 
concentration. Fasting 
serum concentration of full-
length PTH
Yearly 









Age of 8 for individuals 
with a codon 630 
mutation, age of 20 for 
all the others 
Fasting total serum calcium 
concentration (corrected 
for albumin) and/or ionized-
serum calcium 
concentration. Fasting 
serum concentration of full-
length PTH
Yearly 
Age of 8 for individuals 
with a codon 630 
mutation, age of 20 for 
all the others 
Biochemical screenings for 
pheochromocytoma 
Yearly 
C515S;  G533C;  
R600Q;  K603E;  
Y606C;  T636P;  
K666E;  E768D 
Age of 20 Fasting total serum calcium 
concentration (corrected 
for albumin) and/or ionized-
serum calcium 
concentration. Fasting 
serum concentration of full-
length PTH 
Yearly 
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dividuals from a mutation-bearing family indicates that they
are not at risk of develop the disease in the future, and leads
to the decision for no further routine invasive medical analy-
ses.  The MEN1 genetic test can also direct the type of sur-
gical intervention in subjects with parathyroid adenoma. A
positive test strongly suggests to perform a total parathy-
roidectomy (with an intra-operative PTH dosage to individu-
ate and remove also possible supra-numerary and/or ectopic
parathyroid glands), to prevent future recurrences of
parathyroid tumours. This surgical approach is often associ-
ated with re-implantation of healthy, fresh or cryo-preserved
parathyroid tissue in the non-dominant forearm, to avoid the
necessity of a second intervention at neck site in case of
adenoma recurrence. In case of a positive MEN1 test, it is
also recommended to perform a prophylactic thymectomy, at
the same time of parathyroid intervention, to prevent the oc-
currence of thymic carcinoids that are one of the main cause
of morbidity and mortality of MEN1 syndrome, and/or to re-
move intrathymic ectopic/supra-numerary parathyroids. Con-
versely, a negative MEN1 test leads to surgical ablation of
only the adenomatous or hyperplastic parathyroid gland.
Currently, the worldwide most common used genetic testing
for MEN1 encompasses the sequencing of encoding regions
(exons 2-10) and intron-exon junctions of MEN1 gene. Gene
sequencing fails to find mutations of MEN1 coding region
and splice sites in about 10% of MEN1 families and MEN1
sporadic cases (5). It has been estimated that 1-3% of all
MEN1 germline mutations are large deletions within the gene
that cannot be detected by sequencing method. In case of a
sequencing negative test in a MEN1 family and/or in a spo-
radic case presenting the clinical signs of MEN1 syndrome,
MEN1 gene should be screened by multiple ligation-depen-
dent probe amplification (MPLA), a PCR-based gene dosage
procedure that allows to detect large nucleotide deletions
within the gene (7). If also MPLA test fails to find mutations,
it is possible to perform a haplotypes linkage analysis (using
microsatellite markers flanking the 11q13 locus) in families
with at least two generations of affected individuals, to indi-
viduate a haplotypes, which segregates with the disease. A
negative test may also indicate the presence of a pheno-
copy, due to a different genetic alteration. Less than 2% of
MEN1 patients without any MEN1 mutation may bear a mu-
tation in CDKN1A (OMIM gene 116899), CDKN1B (OMIM
gene 600778), CDKN2B (OMIM gene 600431), CDKN2C
(OMIM gene 600927) genes, encoding respectively p21Cip1,
p27Kip1, p15Ink4b, and p18Ink4c, cyclin-dependent kinase in-
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MEN4 CDKN1B ATG-7G>C  N.A. N.A. N.A. 
G9R N.A. N.A. N.A. 
c.59_77dup19 
(K25fs) 
N.A. N.A. N.A. 
P69L N.A. N.A. N.A. 
W76X N.A. N.A. N.A. 
P95S N.A. N.A. N.A. 
P133T N.A. N.A. N.A. 
Stop1>Q N.A. N.A. N.A. 
FHH1 CaSR Any inactivating 
CaSR mutations 
N.A. N.A. N.A. 
FHH2 GNA11 Ile199Del N.A. N.A. N.A. 
FHH3 AP2S1 R15C;  R15L;  R15H N.A. N.A. N.A. 
NSHPT CaSR Homozygote 
inactivating CaSR 
mutations 
N.A. N.A. N.A. 
HPT-JT CDC73 (HRPT2) Any inactivating 
CDC73 mutation 
N.A Fasting total serum calcium 
concentration (corrected 
for albumin) and/or ionized-
serum calcium 
concentration. Fasting 
serum concentration of full-
length PTH 
Every 6-12 months 
N.A Panoramic jaw X-ray with 
neck shielding 
Every 5 years 
N.A. Abdominal MRI Every 5 years 
N.A.   Transvaginal or 
transabdominal ultrasound 
(only in women) 
Yearly 






Continued from Table 2.
N.A. = not available.
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hibitors (CDKI) that negatively regulate cell cycle progres-
sion and cell growth (8). Loss-of-function mutations of one of
these genes have been described to contribute to tumorigen-
esis (9, 10). Interestingly, it has also been demonstrated that
menin directly targets CDKN1B and CDKN2C genes (11). In
particular, inactivating mutations of the CDKN1B gene have
been associated to the MEN4 syndrome (as further de-
scribed below). Patients presenting an inactivating mutation
of one of these CDKI genes are at risk of developing all the
MEN1-associated main tumours, including parathyroid multi-
ple adenomas, in a similar manner of subjects bearing a
MEN1 mutation. A genetic screening of these genes should
be considered in patients presenting a clinical MEN1-like
phenotype but with a MEN1 gene negative test. 
In addition, recently, Circelli et al. (12) exerted the prognostic
role of the Val109Gly (V109G) polymorphism (rs2066827) in
the exon 1 of CDKN1B gene, in patients affected by MEN1
syndrome. Authors found that, in MEN1 patients bearing a
MEN1 mutation, the biallelic presence of  the genetic variant
guanine at nucleotide 326, encoding for the glycine, was sig-
nificantly associated to a more aggressive course of the dis-
ease and a worse prognosis. The presence of glycine at po-
sition 109 presumably alters the interaction with Jun activa-
tion domain-binding protein 1, enhancing the nuclear export
and degradation of  p27Kip1, and it has been correlated with
low nuclear level of this protein. The hypothesis is that the
simultaneous presence of a MEN1 mutation and of heterozy-
gote 326G variations may exert synergic oncogenetic ef-
fects, in which MEN1 acts as “driver” gene and CDKN1B
polymorphism as a “modifier” factor of tumorigenesis. Fur-
ther study are needed to verify the utility of V109G polymor-
phism genetic analysis, in MEN1 mutated patients, as a
marker for the guidance of diagnostic and prognostic man-
agement of PHPT and other MEN1-associated tumours. 
Genetic testing in PHPT in multiple endocrine neoplasia
type 2A (MEN2A) 
Multiple endocrine neoplasia type 2 (MEN2; OMIM pheno-
type #171400) is a rare heritable endocrine syndrome char-
acterised by medullary thyroid carcinoma (MTC), unilateral
or bilateral pheochromocytoma and, only in the MEN2A vari-
ant, PHPT (resulting from hyperplasia or adenoma of the
parathyroid glands). MEN2A accounts for about 70-80% of
all MEN2 syndromes. PHTP occurs in 20 to 30% of MEN2A
patients, usually after the third decade of life and in most
cases (>80%) it is asymptomatic (13). Usually, MEN2A-relat-
ed PHPT is mild and may range from a single parathyroid
adenoma to extended multiglandular hyperplasia.  
MEN2 syndrome presents an autosomal dominant pattern of
inheritance. The only identified susceptibility gene associat-
ed with MEN2 is the proto-oncogene RET (REarranged dur-
ing Transfection; locus 10q12.2, OMIM gene 164761), that
encodes a membrane tyrosine kinase receptor protein con-
sisting of: A) an extracellular portion composed by four cad-
herine-like domains, a calcium-binding site and a cysteine-
rich domain; B) a single-pass transmembrane domain and C)
an intracellular portion containing two distinct tyrosine kinase
domains. Mutation in one of the allele of RET gene (inherited
by parent in familial form or developed at embryo stage in
sporadic form) is sufficient to develop MEN2 syndrome, ac-
cording to dominant mutation of oncogenes. Mutations of
RET in the cysteine-rich domain and in the tyrosine kinase
domains result all in a constitutive tyrosine kinase activation
of the mutant receptor. 
RET germline high-penetrance gain-of-function mutations at
one of six cysteines in the extracellular cysteine-rich domain
of RET (codons 609, 611, 618, 620, 630 and 631 in exon 10
and codon 634 in exon 11) have been found in about 98% of
MEN2A families (14). Therefore, these loci have been identi-
fied as disease-associated hot spots. The most common mu-
tation is the amino acid substitution at codon 634, particular-
ly C634R, that has been found in about 85% of MEN2A pa-
tients, and strongly associated to PHPT (15). A strong corre-
lation between RET specific mutation and MEN2 clinical phe-
notype is well assessed. Thus, the results of genetic test on
RET allow a very specific preventive clinical intervention for
mutation carriers. The presence of mutations in exons 10
and 11 of RET gene is indicative of a MEN2A variant with a
15-30% risk to develop PHPT. Mutations in other RET exons
(i.e. mutations at codon 883 in exon 15 and at codon 918 in
exon 16) have been associated to the MEN2B variant of the
syndrome that does not develop PHPT, thus, a genetic test
indicating mutations in these two exons permits to exclude
the possibility to develop PHPT in the future. 
Due to the strong genotype-phenotype correlation, RET ge-
netic test largely directs the planning of medical interventions
in mutation carriers, with a major focus on the prophylactic
thyroidectomy, to prevent MTC. Anyway, even if MEN2A-as-
sociated PHPT is usually mild and asymptomatic, a genetic
test indicating a MEN2A variant is helping in leading to spe-
cific PHPT biochemical screenings and in early treating this
associated disorder, to prevent morbidity due to chronic hy-
percalciuria, renal calculi, secondary osteoporosis, etc. In
MEN2A carriers of mutations at codons 630 and 634, annual
biochemical analyses for serum calcium concentration and
serum PTH level are recommended since the age of 8 (15)
(Table 2). For carriers of other mutations associated to
MEN2A, annual PHPT biochemical screening should begin
since 20 years of age (16) (Table 2). Since PHPT in MEN2A
is usually mild and asymptomatic, prophylactic parathy-
roidectomy is not usually recommended, even at the time of
neck surgery for medullary thyroid carcinoma. 
Genetic testing in PHPT in multiple endocrine neoplasia
type 4 (MEN4)
Multiple endocrine neoplasia type 4 (MEN4; OMIM pheno-
type #610755) is an extremely rare inherited multiglandular
tumoural syndrome presenting a MEN1-like clinical pheno-
type with a penetrance of 100% of PHPT, caused by para -
thyroid hyperplasia or adenomas, and reported cases of as-
sociated pituitary adenomas (GH- or ACTH-secreting), and
duodenal, pancreatic and stomach lesions. Human MEN4
cases do not usually harbor MEN2-like tumours, unlike in the
murine MENX model, which develops tumours that overlap
both MEN1 and MEN2 syndromes (i.e. parathyroid adeno-
mas, bilateral pheochromocytomas, thyroid C cell hyperpla-
sia, endocrine pancreas hyperplasia and paragangliomas).
The spectrum of MEN4-associated tumours is highly variable
between affected subjects, like in the MEN1 syndrome.
MEN4 affected individuals may present as a MEN1 clinical
phenotype, but without MEN1 mutations (phenocopy). How-
ever, all  the MEN4 patients, described to date, have shown
a relatively late age of  clinical manifestation with respect to
MEN1 counterpart. Also in MEN4, the PHPT has a high pen-
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etrance, and it is the first diagnosed endocrinopathy in most
cases, but with an age at onset more than two decades later
than in MEN1 patients (40-50 years in MEN4 versus 20-25
years in MEN1).
Today is well assessed that MEN4 is a novel form of multiple
endocrine neoplasia caused by inactivating mutations in the
CDKN1B gene (12p13 locus, OMIM 600778) that encodes
the p27kip1 cyclin-dependent kinase inhibitor (17). p27kip1 is a
negative key regulator of cell cycle progression by acting as
kinase inhibitor protein for cyclin-dependent kinase, thus,
preventing their association with cell cycle-regulating cyclin
and inducing cell cycle arrest at G1-to-S-phase transition.
The functional disruption of p27kip1 (presumably due to the
reduction of nuclear localization of the protein in association
with an increased degradation at cytoplasmatic level) is re-
sponsible for uncontrolled cell cycle progression in neuroen-
docrine cells, in which is presumable that the lack of p27kip1
activity cannot be compensated by other cyclin-CDK in-
hibitors. Therefore, the p27kip1 absence plays a crucial role in
induction and progression of neuroendocrine tumorigenesis.
CDKN1B mutations might explain part of the suspected
MEN1 clinical cases lacking MEN1 gene mutations. Se-
quencing of CDKN1B gene is a recommended analysis for
differential diagnosis between MEN1 and MEN4 syndromes,
and it is strongly suggested in all MEN1 phenotypes in which
the MEN1 gene is negative for mutations.
To date, 9 different germline CDKN1B mutations, affecting
the coding region and the 5’ untranslated region (5’-UTR) of
the gene, have been identified in patients with MEN1-like
clinical phenotype (MEN1 phenocopies) but negative for
MEN1 mutations (18, 19). However, given the limited num-
ber of described MEN4 patients, the clinical penetrance of
the disease, the precise tumour spectrum of the syndrome
and a clear association between specific mutation and clini-
cal phenotype is still not well defined, and no suggested
guidelines for biochemical and instrumental preventive
screenings in mutation carriers are not yet available. 
Recently, a case of apparently sporadic early onset PHPT
(no family history of calcium or other endocrine disorders
has been reported and both parents had a normal serum cal-
cium level) has been described in a 15-year-old girl present-
ing recurrent renal calculi, persistent elevated serum calcium
level, and a single gland parathyroid adenoma in the anterior
mediastinum, associated with a novel heterozygote mis-
sense mutation in exon 1 of the CDKN1B gene (c.378G>C),
resulting in an amino acid substitution at position 126
(Glu126Asp) (20). Interestingly, both her mother (46 years)
and her maternal grandfather (74 years) carried the same
heterozygote mutation but they presented normal calcium
and PTH serum levels and no signs or symptoms of PHPT.
Genetic testing in PHPT in familial hypocalciuric 
hypercalcaemia (FHH)
Familial hypocalciuric hypercalcaemia (FHH) comprises a
group of rare hereditary disorders of calcium homeostasis,
characterised by lifelong hypercalcaemia, usually asymp-
tomatic, and by inappropriately low urinary calcium excre-
tion. FHH type 1 variant (FHH1; OMIM phenotype #145980),
that accounts for approximately 65% of all FHH cases, and
FHH type 2 variant (FHH2; OMIM phenotype 145981) are
usually associated with high-normal PTH and mild hyper-
magnesemia. FHH type 3 variant (FHH3; OMIM phenotype
600740) presents different clinical characteristics that in-
clude increased serum PTH, hypophosphatemia and osteo-
malacia. These disorders can be easily misdiagnosed as
PHPT because of the numerous their clinical overlaps, espe-
cially considering mild, asymptomatic forms of PHPT. How-
ever, differentiating between FHH syndromes and sporadic
PHPT is fundamental since these two disorders require radi-
cally different therapies (i.e. almost all of FHH 100% of cas-
es do not require parathyroidectomy, as opposed to PHPT). 
All the three variants of FHH are autosomal dominant heredi-
tary disorders. Specific genetic tests can be very useful for
the differential diagnosis between FHH and PHPT and also
to discriminate between the three FHH variants. 
FHH1 is caused by a heterogeneous group of heterozygote
loss-of-function mutations in calcium sensing receptor
(CaSR) gene, at chromosome 3q21.1 (OMIM gene 601199).
This gene encodes for a G-protein trans-membrane receptor,
widely expressed in parathyroids and kidney tubule and re-
sponsible for the maintaining of stable extracellular calcium
ion level. Inactivating mutations of CaSR result in a receptor
relatively insensitive to serum calcium level. At parathyroid
level, a less sensitive CaSR results in a continuous release
of PTH even when serum calcium is high, resulting in a mild,
usually asymptomatic, hypercalcaemia, hypocalciuria and
high normal to elevated serum magnesium levels. Biochemi-
cal variations in FHH are supposed to be mutation depen-
dent (21). A study by Ward et al. (22) evidenced that CaSR
truncating mutations, presumably not exhibiting a dominant-
negative effect (i.e. a mutation whose gene product adverse-
ly affects the wild type gene product function), are associat-
ed to a less severe hypercalcaemia and a minor increasing
of PTH level, than CaSR missense mutations responsible for
a protein dominant-negative effect. However, different types
of inactivating mutations do not correlate with urinary calci-
um excretion, calcium/creatinine clearance nor with clinical
symptoms. Over 200 different CaSR mutations, mostly mis-
sense mutations, have been described and reported in the
CaSR database (http://www.casrdb.mcgill.ca). 
Conversely, heterozygous activating mutations of CaSR
gene are responsible for the development of autosomal dom-
inant hypocalcemia (HYPOC1; OMIM phenotype #601198), a
rare hereditary disorder of calcium homeostasis charac-
terised by persistent mild, usually asymptomatic hypocal-
cemia, inappropriately normal PTH level and high urinary
calcium excretion. Activating CaSR mutations induce an in-
creased sensitisation of receptor to extracellular calcium
that, at parathyroid level, is responsible for the induction of a
chronic hypocalcemia, and, at kidney level, determines a mi-
nor reabsorption of calcium with subsequent constant hyper-
calciuria and risk of renal stones and nephrocalcinosis. 
Twenty-seven polymorphisms have been identified within the
CaSR gene locus, but no definitive results are available
about their possible role in susceptibility to FHH1 and/or spo-
radic form of PHPT or ADH (23).
FHH2 has been originally mapped to chromosome 19p. Re-
cently, inactivating mutations in G-protein alpha 11 (GNA11,
OMIM gene 139313) have been identified as cause of the
disease. Normally, elevated concentrations of extracellular
calcium ion activate CaSR, and in turn GNA11, resulting in a
reduction of PTH production and secretion. The presence of
an inactivating mutation in GNA11 protein alters the switch
from guanosine diphosphate (GDP) to guanosine triphos-
phate (GTP), thus, reducing CaSR-induced signal transduc-
tion, inducing a constitutive secretion of PTH and leading to
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FHH2 syndrome. Loss-of-function heterozygous 3-bp (CAT)
deletion, leading to an in-frame deletion of Ile200 (Ile200del)
has been identified in a family affected by FHH2, co-segre-
gating only with affected members. This genetic variation
was not found in 120 alleles from 60 unrelated normocal-
cemic individuals, thereby indicating that it was not a com-
mon benign polymorphism but a real disease-predisposing
mutation. Also a missense Leu135Gln mutation has been
identified in a patients affected by FHH2. Both these two
loss-of-function mutations of GNA11 gene disrupt the protein
structure leading to a decreased sensitivity of cells express-
ing CaSR to the extracellular changes in calcium level. Con-
versely, gain-of-function mutations of GNA11 increase cell
sensitivity to extracellular calcium variations and cause the
autosomal dominant hypocalcemia type 2 syndrome (ADH2,
OMIM phenotype #615361) (24). 
FHH3 has been associated to missense heterozygote loss-
of-function mutations at codon 15 off the adaptor protein 2
sigma 1 (AP2S1; locus 19q13.3, OMIM 602242) which is a
protein necessary for the membrane trafficking of the CaSR.
Inactivating mutations of AP2S1 protein decrease the ex-
pression of CaSR at cell membrane level, reducing cell sen-
sitivity to extracellular calcium variations. All AP2S1 muta-
tions identified to date affect the Arg15 residue (Arg15Cys,
Arg15His or Arg15Leu), indicating this amino acid as a prob-
able mutational hotspot for FHH3. No correlation between
different mutations and a specific clinical phenotype has
been found. Mutations at Arg15 in AP2S1 gene are suspect-
ed to be the genetic cause of FHH in more than 20% of pa-
tients without CaSR mutations (25). Therefore, the genetic
screening of AP2S1 codon 15 is strongly suggested in all
FHH-suspected patients proven negative for CaSR muta-
tions, given the clinical benefits (i.e. avoiding unnecessary
parathyroidectomy) that have already been demonstrated for
CASR screening in FHH1. Conversely to CaSR and GNA11,
gain-of-function AP2S1 mutations have not been identified to
date.
Genetic testing in neonatal severe primary 
hyperparathyroidism (NSHPT)
Neonatal severe primary hyperparathyroidism (NSHPT;
OMIM phenotype #239200) is a very rare autosomal reces-
sive disorder and the most severe form of FHH. It consists of
PHPT occurring at birth or within the first six months of life,
causing life-threatening severe hypercalcaemia, hypotonia,
bone demineralization, fragility fractures and respiratory dis-
tress. It is a very severe hereditary disease for which the sur-
vival of children depends on early diagnosis and total
parathyroidectomy. NSHPT is the homozygous form of FHH,
caused by inactivating mutations of both the allele of CaSR
gene. 
Prenatal genetic test or genetic test at birth are recommend-
ed when both parents have been resulted to be carriers of
CaSR mutations and/or present clinical signs of FHH.
Genetic testing in hereditary hyperparathyroidism-jaw
tumour (HPT-JT) syndrome
Hereditary hyperparathyroidism-jaw tumour (HPT-JT; OMIM
phenotype #145001) syndrome is a rare autosomal dominant
disorder encompassing PHPT, ossifying fibromas of jaw
bones (mandible and/or maxilla), polycystic bilateral kidney
lesions, papillary renal carcinoma, renal hamartomas, Wilms’
tumour, and uterine tumours (adenofibromas, leyomiomas or
adenosarcomas) in about 75% of HPT-JT affected women.
Parathyroid tumours occur in about 95% of patients and they
are typically the first clinical manifestation of the syndrome.
PHPT in HPT-JT is characterised by aggressive behaviour
(severe hypercalcaemia with likelihood of hypercalcaemic
crisis) and it is usually associated with parathyroid carcino-
ma in about 10-15% of cases (23). 
Inactivating germline mutations of the tumour suppressor
CDC73 gene (cell division cycle 73 gene, known also as
HRPT2 gene; locus 1q31.2, OMIM gene 607393, encoding
parafibromin) have been described in over 50% of HPT-JT
families and in about 20% of apparently sporadic parathyroid
carcinoma (26). As all tumour suppressor genes, the first
mutation is usually inherited by one of the parent or, in very
rare cases, developed at embryo level, and the second allele
inactivating mechanism is a loss of heterozygosity (LOH) at
somatic level in HPT-JT tumour-related tissues. To date,
over 100 different CDC73 mutations have been described all
along the entire coding region of the gene. The CDC73 pro-
tein, parafibromin, is a nuclear protein acting as a transcrip-
tional regulator within the RNA polymerase II associated
complex, that regulates key transcriptional and post-tran-
scriptional events such as initiation of transcription, transcript
elongation, mRNA maturation and maintenance of poly(A)
length at 3’UTR for mRNA stability. 
The great majority of CDC73 mutations (>80%) is frameshift
or nonsense mutations that determine the functional loss of
parafibromin by causing a premature truncation of this pro-
tein or cause a rapid loosing of the translated protein via
nonsense-mediated mRNA decay. Therefore, the expression
of parafibromin is completely lost in HPT-JT-associated tu-
mour tissues. Immunohistochemical staining of parafibromin
in parathyroid tumours and other HPT-JT- associated tu-
mours is a direct method to recognize HPT-JT syndrome in
patients with already developed tumours. For an early diag-
nosis in asymptomatic subjects from HPT-JT families a se-
quencing screening of CDC73 coding region and exon-intron
junctions is strongly recommended. Moreover, it is estimated
that gross deletions within the gene may represent about 1%
of all CDC73 mutations in HPT-JT pedigrees (27), thus ge-
netic test should encompass the research of CDC73 gross
deletions in HPT-JT families that are negative for point muta-
tions or small frameshift mutations. Even in presence of a
CDC73 mutation, the penetrance of PHPT is incomplete in
HPT-JT patients, and no specific genotype-to-phenotype cor-
relation has been clearly described for each of HPT-JT-asso-
ciated clinical feature. Thus, a positive CDC73 mutational
analysis  is likely to lead not to immediate surgical or phar-
macological therapies, even if it suggests to perform an earli-
er and more frequent instrumental and biochemical screen-
ing. A genetic test identifying an individual as a mutant gene
carrier is indicative for a specific HPT-JT screening program
which comprises dosing of serum calcium and PTH every 6-
12 months for the monitoring of PHPT, panoramic jaw X-ray
with neck shielding every 5 years for the prevention of ossi-
fying jaw fibroma, abdominal MRI every 5 years for the
checking of kidney cystis or tumour and, only in women, an-
nual transvaginal or transabdominal ultrasound screening for
the prevention of uterine tumours and for early identification
of uterine lesions also to improve reproductive fitness (Table
2). In families bearing a CDC73 mutation the genetic analy-
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sis should be performed in children before the age of 10,
since tumours have been also described at that very early
age.
Genetic testing in familial isolated primary 
hyperparathyroidism (FIPH)
Familial isolated primary hyperparathyroidism (FIPH; OMIM
phenotype #145000) is a rare autosomal dominant disorder
characterised by PHPT in various members of the same fam-
ily in the absence of other endocrine clinical manifestations
and/or tumoral lesions. 
A specific genetic cause for FIPH has not been assessed,
and the great majority of FIHP does not have any identifiable
mutation. In families with FIHP, genetic screening for MEN1
and CaSR mutations is suggested when individuals present
mild hypercalcaemia, parathyroid multiglandular involvement
at a relatively young age (before the third decade of life) for
the differential diagnosis and appropriate diagnostic and
therapeutic planning. In FIPH families with parathyroid carci-
noma, cystic parathyroid tumour or jaw tumours the CDC73
genetic screening is mandatory to diagnose/exclude the
HPT-JT syndrome. In up to 14% of FIPH cases mutations of
CDC73 gene have been found (26), suggesting FIPH as a
possible variant of HPT-JT syndrome. FIPH families with a
CDC73 mutations should be enrolled in the biochemical and
instrumental screening program of HPT-JT syndrome. 
Sporadic PHPT
Sporadic PHPT represents about 90-95% of all PHPT cases,
but the causative genetic alterations of PHPT sporadic forms
remain poorly understood. Two main genes have been asso-
ciated to parathyroid adenomas in sporadic PHPT: oncosup-
pressor MEN1 and cyclin D1 gene (CCND1, OMIM gene
168461), both located in chromosome 11. Homozygous loss
of MEN1 locus (caused by two distinct inactivating events at
parathyroid somatic level) has been observed in 25-40% of
sporadic parathyroid tumours (28, 29) and it represents the
most common genetic somatic alteration in sporadic PHPT.
Pericentromeric inversions of chromosome 11, involving the
PTH promoter and the CCND1 gene have been found in 8%
of parathyroid adenomas (30). Cyclin D1 overexpression has
been associated to 20-40% of sporadic parathyroid adeno-
mas (31) and in up to 90% of sporadic parathyroid carcino-
mas (32). 
Some studies (27, 33) have found about 4% of somatic
CDC73 mutations in sporadic parathyroid adenomas. Con-
versely, no mutation of RET and CaSR genes has been de-
tected in sporadic PHPT (34).
Very recently, a study (35) evaluated the involvement of the
AIP gene in a large series of sporadic parathyroid adenomas
by sequencing and MPLA analyses of the AIP gene itself
and by LOH analysis of the AIP locus. In two of 132 tumours
has been identified the R304Q germline mutation, and het-
erozygous AIP locus large deletions have been detected in
29 cases, including one of the two mutated adenomas.
Sanger DNA sequencing on large cohorts of sporadic
parathyroid adenomas or whole exome next generation se-
quencing analysis identified low-frequency germline and so-
matic mutations of other and novel genes, such as inactivat-
ing mutations in the CDKI genes (i.e two CDKN1B mutations
in a total of 86 cases) (36), stabilizing mutations of the beta
catenin (CTNNB1) gene (37-39), an activating mutation
(Y641N) in the histone 3 lysine 27 methyltransferase (EZH2)
gene (found in two of 193 analysed adenomas) (40), and so-
matic mutations (at codons 786 and 787) in the zinc finger X-
linked (ZFX) gene (41). However, a recent work on an Italian
cohort of 12 atypical parathyroid adenomas, 45 typical
parathyroid adenomas and 23 sporadic parathyroid carcino-
mas failed to confirm these results and to detect any muta-
tion of EZH2 and ZFX genes (42). 
For parathyroid carcinomas, inactivating somatic mutations
of the CDC73 gene are the most frequent genetic alteration
ranging from 66 to 100% of cases (43).
No preventive routinely genetic screening is available for
sporadic PHPT since mutations occur only a somatic level
and can be detected only when parathyroid hyperplasia,
adenoma or carcinoma have developed and been surgically
removed. 
Given the relatively high incidence of familial forms of PHPT
(5-10% of cases), a determination of calcaemia/ionized
serum calcium in first-degree relatives of affected individuals
with apparently sporadic parathyroid adenoma is mandatory.
Then, if a familial form is suspected, a genetic testing
(CaSR, MEN1, etc.) is strongly suggested for differential di-
agnosis of PHPT.
Diagnostic genetic workup in PHPT
Since PHPT can be genetically determined in up to 10-15%
of cases, genetic testing has to be considered in the diag-
nostic classification of this disease. In Figure 1 a clinical and
genetic workup is proposed. Even if the proband does not
display a clear positive family for the disease, serum calcium
should always be determined in first-degree relatives. In the
case of positive family history and/or if the patient is young,
genetic testing is advisable even before surgery. If a
multiglandular involvement is detected at the time of parathy-
roidectomy and/or suspicious lesions such as atypical
parathyroid adenoma or carcinoma are diagnosed at histo-
logical examination, genetic testing is mandatory, along with
proper assessment for possible MEN, HPT-JT or FHH asso-
ciated clinical manifestations.
If MEN1-associated manifestations such as neuroendocrine
tumours and/or pituitary adenomas are detected, mutational
analysis of MEN1 gene has to be undertaken. If a MEN1
phenotype is present in the absence of MEN1 mutations, the
exclusion of deletions of 11q13.1 region must be excluded or
confirmed by specific analyses such as multiplex ligation-de-
pendent probe amplification (MLPA). In the case these anal-
yses are negative, sequencing of other genes such as genes
of the CDKI family is advisable.
If a MEN2 is suspected because of high values of serum cal-
citonin, RET mutation analysis is indicated. In addition, the
identification of specific RET mutations associated with a
more aggressive medullary thyroid cancer can induce to per-
form prophylactic thyroidectomy, thus having a deep re-
bound on clinical management in these patients. 
If a relative hypocalciuria for the degree of hypercalcaemia is
detected, in an otherwise asymptomatic patient, sequencing
of the CaSR and other genes encoding for proteins associat-
ed with the CaSR signal transduction pathway (AP2S1,
GNA11) is required.
In the case of jaw tumours associated with PHPT, or suspi-
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cious findings at histology (atypical parathyroid adenoma,
parathyroid carcinoma), mutational analysis of CDC73 has to
be performed.
Since no specific and unique genetic alterations have been
identified in FIHP, sequencing of the genes responsible for
the other syndromes, in particular MEN1 and CaSR, can be
carried out. If a MEN1 mutation is detected, a proper follow-
up to unveil possible MEN1-related manifestations other than
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1. Biochemical and instrumental  
regular screenings for the 
specific syndrome-associated 
tumours (see Table 2)  
2. Mutation specific genetic 





1. High probability of sporadic PHPT 
2. Very low likelihood of a MEN1, MEN2  
or MEN4 syndrome or FHH and HPT-JT 
Figure 1 - Proposed genetic testing workup in patients with primary hyperparathyroidism (PHPT) as derived from the Consensus Statement of the Fourth
International Workshop on Primary Hyperparathyroidism (modified from ref. 33). *CaSR, AP2S1 and GNA11 are examined in the case of familial hy-
percalciuric hypercalcemia (FHH).
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PHPT can be planned (Table 2).
Once a mutation has been identified in the proband, first de-
gree family members have to be screened for that particular
genetic defect, even if asymptomatic, and a proper baseline
assessment and follow-up has to be planned according to
clinical guidelines for the management of that particular syn-
drome (Table 2). If a phenotype-to-genotype correlation ex-
ists, the identification of a particular mutation may influence
the management of the disease itself.
A positive test could also enable the performing of prenatal
tests in the foetus of a mutated individual in order to assess
the genetic status of the foetus before birth, giving parents
the change of termination of affected pregnancies or, alter-
natively, giving clinicians the opportunity to intervene with
prevention protocols and therapies just after birth. In a muta-
tion-positive pedigree also pre-implantation tests could be
performed on embryos derived from in vitro fertilization, in a
couple with one parent bearing a PHPT-associated genetic
mutation, in order to positively select non-mutated embryos
before uterus implantation.  
Recently, the proceedings of the fourth International work-
shop on PHPT have been published (44). They resume the
Consensus achieved by the group meeting and the State-
ment for the diagnosis of asymptomatic primary hyper-
parathyroidism. A detailed section about the genetic testing
for the differential diagnosis of familial PHPT and hypercal-
caemia is reported. In the presence of an isolated PHPT
case (i.e in the absence of other specific syndromic charac-
teristics) the recommended guidelines for mutation screening
in order of likely frequency are MEN1, CASR, AP2S1,
GNA11, CDC73, CDKN1A/1B/2C, RET, and PTH genes. 
Conclusions
Genetic and molecular alterations underlying the different fa-
milial forms of PHPT are highly variable. The increasing
knowledge on molecular pathophysiology of hereditary PH-
PT, together with application of specific genetic tests have
contributed to the availability of more effective and individu-
alised prevention and treatments, granting patients a reduc-
tion of PHPT-associated morbidity and a better quality of life. 
Some points should be highlighted: 1) genetic test in all fami-
ly members of mutation-bearing pedigrees is fundamental
because of the autosomal dominant pattern of inheritance; 2)
the identification of mutation carriers, even the asymptomatic
ones, is important for the prevention and therapeutic choic-
es; 3) the recognition of the specific mutated gene, and in
some cases of the specific mutation, is pivotal for the plan-
ning of future preventive screenings and for clinical deci-
sions; 4) a positive test can lead to a decision for an in vitro
fertilisation with pre-implantation genetic selection of non-
mutated embryos or to a decision for a pre-natal genetic test;
5) a negative test allows individuals to avoid future periodic
syndrome-related screenings.
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